ALAGRA Suspension

Therapeutic Class

Antihistamines & Antiallergics


Fexofenadine (Alagra) is indicated for the relief of the symptoms associated with Seasonal allergic rhinitis, sneezing, rhinorrhea, itchy nose / palate / throat, itchy /watery/red eyes. Fexofenadine also indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria. It significantly reduces pruritus and the number of wheal & flare.

Chemical Composition

Alagra Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg.


50 ml/ Bot

Dosage & Administration

Adults and children aged 12 years and older: Seasonal Allergic Rhinitis, Chronic Idiopathic Urticaria. Dose: 60 mg twice daily or 120 mg once daily. In severe case: 180 mg once daily (A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function). Children 6 months to less than 2 years: Chronic Idiopathic Urticaria. Dose: 15 mg or 2.5 ml twice daily (For pediatric patients with decreased renal function, the recommended starting dose is 15 mg once daily). Children 2 to 11 years: Seasonal Allergic, Rhinitis , Chronic, Idiopathic Urticaria. Dose: 30 mg or 5 ml twice daily (For pediatric patients with decreased renal function, the recommended starting dose is 30 mg once daily)


Fexofenadine is contraindicated in patients with known hypersensitivity to any of its ingredients.

Warning & Precautions

Limited data is available in the elderly and renally or hepatically impaired patients. Fexofenadine should be administered with care in these special groups.

Side Effects

The adverse effects that may be observed when treated with Fexofenadine are headache, dyspepsia, fatigue, drowsiness, dizziness, nausea, chest tightness, dyspnoea etc.

Drug Interaction

Co-administration of Fexofenadine Hydrochloride with Ketoconazole and Erythromycin led to increased plasma levels of Fexofenadine Hydrochloride. Administration of Fexofenadine with Aluminium and Magnesium containing antacids 15 minutes prior to Fexofenadine caused a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. It is advisable to leave 2 hours between administration of Fexofenadine and Aluminium & Magnesium hydroxide containing antacids.